Rom S. Leidner

6.0k total citations · 3 hit papers
94 papers, 3.7k citations indexed

About

Rom S. Leidner is a scholar working on Oncology, Immunology and Otorhinolaryngology. According to data from OpenAlex, Rom S. Leidner has authored 94 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 41 papers in Immunology and 17 papers in Otorhinolaryngology. Recurrent topics in Rom S. Leidner's work include Cancer Immunotherapy and Biomarkers (48 papers), Immunotherapy and Immune Responses (26 papers) and CAR-T cell therapy research (24 papers). Rom S. Leidner is often cited by papers focused on Cancer Immunotherapy and Biomarkers (48 papers), Immunotherapy and Immune Responses (26 papers) and CAR-T cell therapy research (24 papers). Rom S. Leidner collaborates with scholars based in United States, United Kingdom and Netherlands. Rom S. Leidner's co-authors include R. Bryan Bell, Bernard A. Fox, Walter J. Urba, Carlo Bifulco, David M. Aboulafia, Andrew D. Weinberg, Ryan Montler, Shu‐Ching Chang, Marka R. Crittenden and Rebekka Duhen and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rom S. Leidner

89 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

2018 564 citations Rebekka Duhen, Tiffany C. Blair et al. Nature Communications profile →
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

2019 491 citations Ezra E.W. Cohen, R. Bryan Bell et al. Journal for ImmunoTherapy of Cancer profile →
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

2022 319 citations Rom S. Leidner, David E. Sprott et al. profile →

Peers

Countries citing papers authored by Rom S. Leidner

Since Specialization

Citations

This map shows the geographic impact of Rom S. Leidner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rom S. Leidner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rom S. Leidner more than expected).

Fields of papers citing papers by Rom S. Leidner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rom S. Leidner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rom S. Leidner. The network helps show where Rom S. Leidner may publish in the future.

Co-authorship network of co-authors of Rom S. Leidner

This figure shows the co-authorship network connecting the top 25 collaborators of Rom S. Leidner. A scholar is included among the top collaborators of Rom S. Leidner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rom S. Leidner. Rom S. Leidner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TRIALSCOPE — A Framework for Clinical Trial Simulation from Real-World Data 2025 ·NEJM AI ·(unknown), (unknown), Cliff Wong, Zelalem Gero, Jaspreet Bagga, Isabel Chien, (unknown), Emre Kıcıman, (unknown), Roshanthi Weerasinghe, Rom S. Leidner, Brian Piening, Tristan Naumann, Carlo Bifulco, Hoifung Poon	2
2	Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma 2025 ·Journal for ImmunoTherapy of Cancer ·Robert L. Ferris, Rom S. Leidner, Christine H. Chung, Antonio Jimeno, Sylvia M. Lee, Ammar Sukari, Jorge J. Nieva, Juneko E. Grilley‐Olson, Rebecca Redman, Stuart J. Wong, Victoria Villaflor, Jamal Misleh, Friedrich Graf Finckenstein, Jeffrey Chou, Brian Gastman, Rana Fiaz, (unknown), Min Yi, Ezra E.W. Cohen	1
3	An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation. 2024 ·Journal of Clinical Oncology* ·Salman R. Punekar, Meredith Pelster, Carlos Becerra, J. Randolph Hecht, Andrew Scott Paulson, Patrick Grierson, Maria Pia Morelli, Rom S. Leidner, Mandana Kamgar, Joaquina Baranda, Syed Mohammad Ali Kazmi, Ardaman Shergill, Anne Robinson, Anuradha Patel, (unknown), Jeroen van Heijst, Nathan Demars, Arianne Perez, Sarah S. Cohen, Marwan Fakih	3
4	Clinical impact for advanced non-small-cell lung cancer patients tested using comprehensive genomic profiling at a large USA health care system 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Alessandro De Vita, Douglas Hanes, Bela Bapat, Shu‐Ching Chang, (unknown), Mark Schmidt, Cliff Wong, Hoifung Poon, Brock E. Schroeder, Roshanthi Weerasinghe, Rachel E. Sanborn, Rom S. Leidner, Walter J. Urba, Carlo Bifulco, Brian Piening	2
5	Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System 2024 ·JCO Oncology Practice ·(unknown), (unknown), (unknown), Bela Bapat, Douglas Hanes, Shu‐Ching Chang, (unknown), Cliff Wong, Hoifung Poon, Brock E. Schroeder, Roshanthi Weerasinghe, Rom S. Leidner, Walter J. Urba, Carlo Bifulco, Brian Piening	2
6	Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors. 2024 ·Journal of Clinical Oncology ·Sajeve Thomas, (unknown), Brian S. Henick, Rom S. Leidner, (unknown), (unknown), Jared Weiss, Michael E. Hurwitz, Jaspreet Singh Grewal, Jason J. Luke, Shrikanta Chattopadhyay, Yun Wang, (unknown), J. A. H. Murray, Débora Barton, (unknown), Gavin MacBeath, Justin C. Moser	0
7	NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer 2024 ·International Journal of Biological Sciences ·Junping Li, (unknown), Hui Lian, Shuo Yang, Manting Liu, (unknown), Bihui Cao, Dongni Chen, Yuling Hu, (unknown), Yan Shen, Xiaodie Ye, (unknown), Ming Zhao, Weijun Fan, (unknown), Rom S. Leidner, Qingde Wu, Lili Yang, Zhenfeng Zhang	14
8	FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment 2023 ·Cancer Immunology Research ·David A. Knorr, Lucas Blanchard, Rom S. Leidner, Shawn M. Jensen, (unknown), Andrew Jones, Carmen Ballesteros‐Merino, R. Bryan Bell, (unknown), (unknown), David E. Sprott, Carlo Bifulco, Brian Piening, Rony Dahan, Juan C. Osorio, Bernard A. Fox, Jeffrey V. Ravetch	18
9	Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study 2023 ·Cancer Research ·Kathryn F. Mileham, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, (unknown), Carmen Calfa, (unknown), Alissa Marr, Eugene R. Ahn, Deepti Behl, Michael J. Hall, Inderjit Mehmi, (unknown), Rom S. Leidner, Mark M. Zalupski, (unknown), (unknown), Susan Halabi, Richard L. Schilsky	1
10	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial 2021 ·Journal for ImmunoTherapy of Cancer ·Robert L. Ferris, William C. Spanos, Rom S. Leidner, Anthony Gonçalvès, Uwe M. Martens, Chrisann Kyi, William H. Sharfman, Christine H. Chung, Lot A. Devriese, Hélène Gauthier, (unknown), Lazar Vujanović, Janis M. Taube, Julie E. Stein, Jun Li, Bin Li, Tian Chen, (unknown), Suzanne L. Topalian	126
11	Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors 2021 ·Cancer ·Corey C. Foster, Marcus Couey, Sara Kochanny, Arun Khattri, Rajesh Acharya, Yi‐Hung Carol Tan, Ryan J. Brisson, Rom S. Leidner, Tanguy Y. Seiwert	53
12	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells 2021 ·Nature Communications ·Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu‐Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg	114
13	Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma 2021 ·Journal for ImmunoTherapy of Cancer ·Rom S. Leidner, Marka R. Crittenden, Kristina H. Young, Hong Xiao, Yaping Wu, Marcus Couey, Ashish Patel, Allen Cheng, Amber L. Watters, Carlo Bifulco, George Morris, (unknown), (unknown), Walter J. Urba, Michael J. Gough, R. Bryan Bell	120
14	Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris, John D. Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James Ohr, (unknown), Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M. Townsley, Sandip Pravin Patel	63
15	976TiP SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer 2020 ·Annals of Oncology ·(unknown), Lara Dunn, (unknown), Michael K. Gibson, Rom S. Leidner, P. Savvides, (unknown), Trupti Trivedi, (unknown), (unknown), (unknown), (unknown)	2
16	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies 2019 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Melissa L. Johnson, A. Craig Lockhart, Kathleen N. Moore, Gerald S. Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Lee S. Rosen, Glen J. Weiss, Rom S. Leidner, Jingjin Li, Anne Paccaly, Minjie Feng, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury, Marka R. Crittenden	50
17	Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma 2018 ·Cancer Research ·Jason R. Baird, R. Bryan Bell, Victoria Troesch, David J. Friedman, Shelly Bambina, Gwen Kramer, Tiffany C. Blair, Terry R. Medler, Yaping Wu, Zhaoyu Sun, Tanja D. de Gruijl, Rieneke van de Ven, Rom S. Leidner, Marka R. Crittenden, Michael J. Gough	54
18	Aberrant Vimentin Methylation Is Characteristic of Upper Gastrointestinal Pathologies 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Helen Moinova, Rom S. Leidner, Lakshmeswari Ravi, James Lutterbaugh, Jill S. Barnholtz‐Sloan, Yanwen Chen, Amitabh Chak, Sanford D. Markowitz, Joseph Willis	34
19	Recrudescent Kaposi's Sarcoma After Initiation of HAART: A Manifestation of Immune Reconstitution Syndrome 2005 ·AIDS Patient Care and STDs ·Rom S. Leidner, David M. Aboulafia	9
20	Recrudescent Kaposi's Sarcoma After Initiation of HAART: A Manifestation of Immune Reconstitution Syndrome 2005 ·AIDS Patient Care and STDs ·Rom S. Leidner, David M. Aboulafia	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact